hotspot -WSS

hotspot

author：leisure time 2025-10-01 15:29:29 - browse：3

insulin biosimilar — Last week, the FDA released a trio of guidelines clarifying the way they plan to evaluate devices that go through the 510(k) pathway. Jacquelyn Martin/AP

Five years after promising to fix a flawed regulatory pathway widely used by medical device manufacturers, the Food and Drug Administration has issued new guidelines to improve its so-called 510(k) program that has long been lambasted for letting risky devices fall through the cracks.

Most medical device companies do not have to test their products on people in order to secure clearance from the FDA — they simply have to show they’re “substantially equivalent” to devices already on the market, called “predicates.” This process is the 510(k) pathway, and accounts for the vast majority of new medical devices launched on the market each year. Devices cleared through this pathway include X-ray machines, muscle stimulators, and wheelchairs.

Last week, the FDA released a trio of guidelines clarifying the way it plans to evaluate devices that go through the 510(k) pathway. The agency is asking manufacturers to avoid predicate devices that were recalled due to a “design-related” issue or have “unmitigated” safety concerns. Manufacturers should submit flow charts explaining why they chose their predicate device. If they have to choose one with a recall history or safety issues, they should explain how the new device addresses those problems. The FDA may also ask the manufacturer for clinical data in this case.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Change Healthcare outage fallout shows need for new oversight

leisure time

explore

WSS

A new study asks: Are we harming blood donors by taking blood?

How many hemophilia patients actually want gene therapy?

Bacterial infection may be ‘key event’ in endometriosis, study says

New case study details death in closely watched Alzhiemer's trial

President Biden's budget: Here's what you might have missed

Grail is spending more than ever lobbying Congress

entertainment

hotspot

hotspot

Moonlake's readout produced a cash windfall. Risks remain

Readout Newsletter: CAR

Anesthesiologist group: stop taking Ozempic before surgery

Option Care buys Amedisys in $3.6 billion home care deal

How one medical school became remarkably diverse

Did the public have the right to know Arthur Ashe had AIDS?

Heart attack and stroke risk calculators need revising

Boston's new lab space is opening empty

After affirmative action ruling, medical educators look to 'holistic review'

Listen: Biogen's messy board & Laronde's data problem

focus

Meta looks to target Twitter with a rival app called Threads

HHS secretary Becerra pressed on Change HealthCare cyberattack

Australia's humpback populations rebound raising hopes of marine scientists

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Boston's new lab space is opening empty

Make 'food is medicine' a key part of White House nutrition meeting

leisure time

explore

leisure time

focus